Sign inCreate account

Report workspace

Add to folder
NCT06690827RECRUITINGanonymous

Clinical Study of CD123 Targeting Chimeric Antigen Receptor NK Cells (CAR-NK) in the Treatment of Relapse/refractory Acute Myeloid Leukemia (AML)or Blastic Plasmacytoid Dendritic Cell Neoplasm(BPDCN)

Sponsor

Source record

Chongqing Precision Biotech Co., Ltd

Phase

Source record

Phase 1

Modality

AI-normalized

small molecule

Target

AI-normalized

CD123 (Cluster of Differentiation 123), a cell surface marker expressed on certain hematological malignancies, targeted by Chimeric Antigen Receptor Natural Killer (CAR-NK) cells.

Indication / condition

AI-normalized

AML (Acute Myeloid Leukemia)

Intervention

Source record

Anti-CD123 CAR NK cells

Source & freshness

Source record

NCT ID

NCT06690827

Original source

ClinicalTrials.gov

Source last updated

Nov 15, 2024

Ingested at

Jun 17, 2026

Internal sync

Jun 17, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT06690827

Title

Clinical Study of CD123 Targeting Chimeric Antigen Receptor NK Cells (CAR-NK) in the Treatment of Relapse/refractory Acute Myeloid Leukemia (AML)or Blastic Plasmacytoid Dendritic Cell Neoplasm(BPDCN)

Sponsor

Chongqing Precision Biotech Co., Ltd

Status

RECRUITING

Phase

Phase 1

Condition raw

AML (Acute Myeloid Leukemia), BPDCN (blastic Plasmacytoid Dendritic Cell Neoplasm)

Condition normalized

AML (Acute Myeloid Leukemia), BPDCN (blastic Plasmacytoid Dendritic Cell Neoplasm)

Modality raw

small molecule

Modality normalized

small molecule

Target raw

CD123 (Cluster of Differentiation 123), a cell surface marker expressed on certain hematological malignancies, targeted by Chimeric Antigen Receptor Natural Killer (CAR-NK) cells.

Target normalized

CD123 (Cluster of Differentiation 123), a cell surface marker expressed on certain hematological malignancies, targeted by Chimeric Antigen Receptor Natural Killer (CAR-NK) cells.

Interventions

Anti-CD123 CAR NK cells

Public preview

Source record

Chongqing Precision Biotech Co., Ltd is advancing a novel CAR-NK cell therapy targeting CD123 for the treatment of relapsed/refractory Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). The trial is currently recruiting and aims to establish safety and efficacy, with potential implications for a significant market given the high unmet need in these malignancies. The competitive landscape includes other CAR-T and NK cell therapies, but the specificity for CD123 may provide a differentiated therapeutic profile. Successful outcomes could position Chongqing Precision Biotech favorably for partnerships or acquisition opportunities in the oncology space.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Clinical Study of CD123 Targeting Chimeric Antigen Receptor NK Cells (CAR-NK) in the Treatment of Relapse/refractory Acute Myeloid Leukemia (AML)or Blastic Plasmacytoid Dendritic Cell Neoplasm(BPDCN)

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 17, 2026

NCT ID

NCT06690827

Status

RECRUITING

Phase

Phase 1

Sponsor

Chongqing Precision Biotech Co., Ltd

Executive brief

Investment-Ready Snapshot

Chongqing Precision Biotech Co., Ltd is advancing a novel CAR-NK cell therapy targeting CD123 for the treatment of relapsed/refractory Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). The trial is currently recruiting and aims to establish safety and efficacy, with potential implications for a significant market given the high unmet need in these malignancies. The competitive landscape includes other CAR-T and NK cell therapies, but the specificity for CD123 may provide a differentiated therapeutic profile. Successful outcomes could position Chongqing Precision Biotech favorably for partnerships or acquisition opportunities in the oncology space.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedNov 15, 2024
Internal syncJun 17, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT06690827

Indication

AML (Acute Myeloid Leukemia)

Modality

small molecule

Target

CD123 (Cluster of Differentiation 123), a cell surface marker expressed on certain hematological malignancies, targeted by Chimeric Antigen Receptor Natural Killer (CAR-NK) cells.

Intervention

Anti-CD123 CAR NK cells

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.